Overview
Sunosi is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).

Coverage Guidelines
Authorization may be granted for members who are currently receiving treatment with Sunosi, excluding when the product is obtained as samples or via manufacturer’s patient assistance programs.

OR
Authorization may be granted for members when all the following criteria are met, and documentation is provided:
1. The member is ≥ 18 years of age
2. The member is using Sunosi to improve wakefulness in those with excessive daytime sleepiness associated with narcolepsy OR obstructive sleep apnea (OSA)
3. The member has had previous trial, inadequate response or contraindication to modafinil AND armodafinil

Continuation of Therapy
Reauthorization requires physician documentation of improvement of member’s condition.

Limitations
Authorizations will be approved for 12 months

References


Review History

01/23/2020 – Reviewed and Approved P&T Mtg (effective 6/1/20)

Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.